Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial
Background: Chronic kidney disease is associated with increased arterial stiffness even in the early stages and this is thought to be a key mediator in the pathophysiology of the increased cardiovascular risk associated with this condition. The use of low-dose spironolactone has previously been show...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2014
|
| _version_ | 1797087921986076672 |
|---|---|
| author | Ng, K Jain, P Heer, G Redman, V Chagoury, O Dowswell, G Greenfield, S Freemantle, N Townend, J Gill, P McManus, R Ferro, C |
| author_facet | Ng, K Jain, P Heer, G Redman, V Chagoury, O Dowswell, G Greenfield, S Freemantle, N Townend, J Gill, P McManus, R Ferro, C |
| author_sort | Ng, K |
| collection | OXFORD |
| description | Background: Chronic kidney disease is associated with increased arterial stiffness even in the early stages and this is thought to be a key mediator in the pathophysiology of the increased cardiovascular risk associated with this condition. The use of low-dose spironolactone has previously been shown to improve arterial stiffness and reduce left ventricular mass safely in early-stage chronic kidney disease in the context of careful monitoring at a university hospital. However, the majority of patients with chronic kidney disease are managed by their general practitioners in the community. It is not known whether similar beneficial effects can be achieved safely using spironolactone in the primary care setting. The aim of this study is to determine whether low-dose spironolactone can safely lower arterial stiffness in patients with stage 3 chronic kidney disease in the primary care setting.Methods/design: STOP-CKD is a multicentre, prospective, randomized, double-blind, placebo-controlled pilot trial of 240 adult patients with stage 3 chronic kidney disease recruited from up to 20 general practices in South Birmingham, England. Participants will be randomly allocated using a secured web-based computer randomization system to receive either spironolactone 25 mg once daily or a matching inactive placebo for 40 weeks, followed by a wash-out period of 6 weeks. Investigators, outcome assessors, data analysts and participants will all be blinded to the treatment allocation. The primary endpoint is improved arterial stiffness, as measured by carotid-femoral pulse wave velocity between baseline and 40 weeks. The secondary endpoints are incidence of hyperkalaemia, change in estimated glomerular filtration rate, change in urine albumin:creatinine ratio, change in brachial blood pressure, change in pulse waveform characteristics and overall tolerability of spironolactone. An additional quality control study, aiming to compare the laboratory serum potassium results of samples processed via two methods (utilizing routine transport or centrifugation on site before rapid transport to the laboratory) for 100 participants and a qualitative research study exploring patients' and general practitioners' attitudes to research and the use of spironolactone in chronic kidney disease in the community setting will be embedded in this pilot study.Trial registration: Current Controlled Trials ISRCTN80658312. © 2014 Ng et al.; licensee BioMed Central Ltd. |
| first_indexed | 2024-03-07T02:42:27Z |
| format | Journal article |
| id | oxford-uuid:aaeb2d91-0c21-4fe3-a54a-7b071625d8c2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:42:27Z |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:aaeb2d91-0c21-4fe3-a54a-7b071625d8c22022-03-27T03:18:25ZSpironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:aaeb2d91-0c21-4fe3-a54a-7b071625d8c2EnglishSymplectic Elements at OxfordBioMed Central2014Ng, KJain, PHeer, GRedman, VChagoury, ODowswell, GGreenfield, SFreemantle, NTownend, JGill, PMcManus, RFerro, CBackground: Chronic kidney disease is associated with increased arterial stiffness even in the early stages and this is thought to be a key mediator in the pathophysiology of the increased cardiovascular risk associated with this condition. The use of low-dose spironolactone has previously been shown to improve arterial stiffness and reduce left ventricular mass safely in early-stage chronic kidney disease in the context of careful monitoring at a university hospital. However, the majority of patients with chronic kidney disease are managed by their general practitioners in the community. It is not known whether similar beneficial effects can be achieved safely using spironolactone in the primary care setting. The aim of this study is to determine whether low-dose spironolactone can safely lower arterial stiffness in patients with stage 3 chronic kidney disease in the primary care setting.Methods/design: STOP-CKD is a multicentre, prospective, randomized, double-blind, placebo-controlled pilot trial of 240 adult patients with stage 3 chronic kidney disease recruited from up to 20 general practices in South Birmingham, England. Participants will be randomly allocated using a secured web-based computer randomization system to receive either spironolactone 25 mg once daily or a matching inactive placebo for 40 weeks, followed by a wash-out period of 6 weeks. Investigators, outcome assessors, data analysts and participants will all be blinded to the treatment allocation. The primary endpoint is improved arterial stiffness, as measured by carotid-femoral pulse wave velocity between baseline and 40 weeks. The secondary endpoints are incidence of hyperkalaemia, change in estimated glomerular filtration rate, change in urine albumin:creatinine ratio, change in brachial blood pressure, change in pulse waveform characteristics and overall tolerability of spironolactone. An additional quality control study, aiming to compare the laboratory serum potassium results of samples processed via two methods (utilizing routine transport or centrifugation on site before rapid transport to the laboratory) for 100 participants and a qualitative research study exploring patients' and general practitioners' attitudes to research and the use of spironolactone in chronic kidney disease in the community setting will be embedded in this pilot study.Trial registration: Current Controlled Trials ISRCTN80658312. © 2014 Ng et al.; licensee BioMed Central Ltd. |
| spellingShingle | Ng, K Jain, P Heer, G Redman, V Chagoury, O Dowswell, G Greenfield, S Freemantle, N Townend, J Gill, P McManus, R Ferro, C Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial |
| title | Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial |
| title_full | Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial |
| title_fullStr | Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial |
| title_full_unstemmed | Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial |
| title_short | Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial |
| title_sort | spironolactone to prevent cardiovascular events in early stage chronic kidney disease stop ckd study protocol for a randomized controlled pilot trial |
| work_keys_str_mv | AT ngk spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT jainp spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT heerg spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT redmanv spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT chagouryo spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT dowswellg spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT greenfields spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT freemantlen spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT townendj spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT gillp spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT mcmanusr spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial AT ferroc spironolactonetopreventcardiovasculareventsinearlystagechronickidneydiseasestopckdstudyprotocolforarandomizedcontrolledpilottrial |